top of page
Our Blog
The DECODR Digest - November 2026
Read the full issue here: The DECODR Digest - November 2026 - Issue 3
DECODR, Inc.
7 days ago1 min read
CRISPR editing analysis: What TIDE and ICE don't show you
We know that you have choices for quantifying CRISPR editing outcomes from standard Sanger sequencing. And you may be tempted to use TIDE or ICE because they are free for most users. But did you know that three independent, peer-reviewed studies compared them unfavorably to DECODR. Here is what they found... CRISPR editing analysis: What TIDE and ICE don't show you
DECODR, Inc.
Oct 211 min read
The DECODR Digest - October 2026
Read the full issue here: The DECODR Digest - October 2026
DECODR, Inc.
Oct 71 min read
The DECODR Digest - September 2026
Read the full issue here: Fall into Knowledge: DECODR September 2026 Newsletter
DECODR, Inc.
Sep 91 min read


ChristianaCare Launches DECODR, Inc., to Bring Advanced, Accurate Gene Editing Analysis to Scientists Worldwide
New company grows out of Gene Editing Institute to accelerate discovery and innovation Article Site: ChristianaCare ChristianaCare’s Gene Editing Institute has launched DECODR, Inc., a new for-profit company created to expand access to one of the world’s leading software tools to evaluate the effectiveness of CRISPR gene editing. The software program grew out of the Gene Editing Institute’s mission to turn cutting edge science into real world solutions that helps patients. No
DECODR, Inc.
May 213 min read


CRISPR Concerns Won't Spoil Its Promise—If We Use the Right Tools
Eric B. Kmiec, PhD The recent approval by the U.S. Food and Drug Administration (FDA) of Casgevy, a therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene editing to treat patients with sickle cell disease, is a watershed moment in the history of this nascent field. I have been involved in gene therapy research for decades. Like many of my peers, I am thrilled that with this incredible breakthrough, CRISPR may be, as one story in GEN noted,
Eric B. Kmiec
Mar 264 min read
bottom of page